C. Schwager

In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system

C. Stemmer, J. Stadlmann, F. Altmann, 2007, Biotechnology journal.

Improved Effector Functions of a Therapeutic Monoclonal

G. Himmler, M. Schuster, G. Waxenecker, 2005 .

Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.

Christian Gerdes, G. Himmler, M. Schuster, 2005, Cancer research.

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase

S. Pleschka, M. Stukova, M. Bergmann, 2017, Molecular therapy oncolytics.

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System

H. Jungwirth, M. Schuster, H. Loibner, 2012, International journal of hypertension.

pDAP2: a vector for construction of alkaline phosphatase fusion-proteins.

G. Himmler, C. Schwager, R. Kerschbaumer, 1996, Immunotechnology : an international journal of immunological engineering.

Establishment of a Chimeric, Replication-Deficient Influenza A Virus Vector by Modulation of Splicing Efficiency

T. Muster, M. Wolschek, M. Bergmann, 2010, Journal of Virology.

Abstract P209: RAS-Equilibrium Analysis: Simplified Biochemical Characterization of the Renin-angiotensin-system and Implications for Diagnosis and Treatment of Hypertension

O. Domenig, M. Poglitsch, C. Schwager, 2015, Hypertension.